<DOC>
	<DOCNO>NCT01805843</DOCNO>
	<brief_summary>Chronic myelogenous leukemia ( CML ) chronic myeloproliferative disorder characterize translocation chromosome 9 22 , lead pathogenic tyrosine kinase signal transduction protein . CML treat tyrosine kinase inhibitor ( TKIs ) , inhibit BCR/ABL kinase , imatinib . In 20 % CML patient treat imatinib , complete cytogenetic response achieve . The two novel TKIs ( dasatinib nilotinib ) , achieve high rate complete cytogenetic response propose second-line therapy imatinib-resistant patient tolerate imatinib . Dasatinib inhibit BCR/ABL kinase &gt; 300 time vitro imatinib also inhibit several kinase , include Src family . Src tyrosine kinase crucial potassium channel function human pulmonary artery . Imatinib nilotinib inhibit Src . Incident case precapillary PH report patient CML treat dasatinib . Improvements usually observe withdrawal dasatinib . This study design identify incident case dasatinib-associated PH describe pulmonary vascular change induce dasatinib . As comparison population patient receive another second-line TKI ( nilotinib ) .</brief_summary>
	<brief_title>Pulmonary Vasculopathy Under Second-line Therapy Chronic Myeloid Leukemia</brief_title>
	<detailed_description>Doppler echocardiography rest perform patient . Patients without exercise capacity limitation exercise test ( Doppler echocardiography spiroergometry ) perform . Patients show elevated SPAP rest exercise ( study SPAP â‰¥ 40 mmHg ) reduce exercise capacity ( peak VO2 &lt; 75 % ) right heart catheterization ( RHC ) suggest . Additionally evaluation exercise capacity 6 MWD perform . This work- patient allow clinical hemodynamic evaluation .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>patient chronic myeloid leukemia secondline therapy dasatinib nilotinib write informed consent Manifest pulmonary hypertension significant pulmonary disease Leftsided heart failure diastolic compliance dysfunction + Hemodynamic relevant valvular disease Systemic arterial hypertension ( rest systolic &gt; 150 mmHg , diastolic &gt; 90 mmHg , exercise &gt; 220 mmHg ) Severe anemia Uncontrolled supraventricular ventricular arrhythmia Myocardial infarction ( within last 12 month ) Pulmonary embolism ( within last 12 month ) Recent therapy change ( within last 12 month ) Recent major surgery ( within last 12 month ) For exercise test : musculoskeletal disease may unable exercise test .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>95 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Pulmonary hypertension</keyword>
	<keyword>chronic myeloid leukemia</keyword>
	<keyword>dasatinib</keyword>
	<keyword>nilotinib</keyword>
</DOC>